Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 433,539	$ 1,910,153
Accounts receivable	78,105	67,994
Inventories	36,907	34,446
Prepaid expenses and other current assets	12,795	4,089
Total current assets	561,346	2,016,682
Equipment, net of depreciation	50,336	59,315
Other non-current assets, net of amortization	31,269	36,729
Total assets	642,951	2,112,726
Current liabilities:
Accounts payable and accrued expenses	344,438	200,103
Accrued officer bonus		80,000
Convertible notes payable	4,830,097	560,000
Discount on convertible notes payable and line of credit, net of amortization	(2,108,435)	(398,910)
Derivative warrant liability	570,595	663,560
Line of credit	50,000	50,000
Deposit	50,000
Total current liabilities	3,736,695	1,154,753
Long-term liabilities:
Convertible notes payable	675,571	5,250,668
Line of credit	250,000
Discount on convertible notes payable and line of credit, net of amortization	(543,483)	(3,522,497)
Total liabilities	4,118,783	2,882,924
COMMITMENTS, CONTINGENCIES (Notes 8 and 9)
STOCKHOLDERS’ DEFICIT:
Convertible Preferred Series A, $.00067 Par Value, 50,000,000 Shares Authorized, -0- Shares Issued and Outstanding, at December 31, 2016 and June 30, 2017.
Common stock, $.00067 Par Value, 200,000,000 Shares Authorized, 92,975,970 and 99,898,718 Shares Issued, at December 31, 2016 and June 30, 2017, respectively.	66,885	62,179
Additional paid-in capital	92,533,290	90,609,774
Accumulated deficit	(96,256,129)	(91,915,426)
Accumulated other comprehensive loss	(97,680)	(81,694)
Total Biolargo stockholders’ deficit	(3,753,634)	(1,325,167)
Non-controlling interest (Note 6)	277,802	554,969
Total stockholders’ deficit	(3,475,832)	(770,198)
Total liabilities and stockholders’ deficit	$ 642,951	$ 2,112,726